Literature DB >> 22733823

Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin.

Lusine H Demirkhanyan1, Mariana Marin, Sergi Padilla-Parra, Changyou Zhan, Kosuke Miyauchi, Maikha Jean-Baptiste, Gennadiy Novitskiy, Wuyuan Lu, Gregory B Melikyan.   

Abstract

The human neutrophil peptide 1 (HNP-1) is known to block the human immunodeficiency virus type 1 (HIV-1) infection, but the mechanism of inhibition is poorly understood. We examined the effect of HNP-1 on HIV-1 entry and fusion and found that, surprisingly, this α-defensin inhibited multiple steps of virus entry, including: (i) Env binding to CD4 and coreceptors; (ii) refolding of Env into the final 6-helix bundle structure; and (iii) productive HIV-1 uptake but not internalization of endocytic markers. Despite its lectin-like properties, HNP-1 could bind to Env, CD4, and other host proteins in a glycan- and serum-independent manner, whereas the fusion inhibitory activity was greatly attenuated in the presence of human or bovine serum. This demonstrates that binding of α-defensin to molecules involved in HIV-1 fusion is necessary but not sufficient for blocking the virus entry. We therefore propose that oligomeric forms of defensin, which may be disrupted by serum, contribute to the anti-HIV-1 activity perhaps through cross-linking virus and/or host glycoproteins. This notion is supported by the ability of HNP-1 to reduce the mobile fraction of CD4 and coreceptors in the plasma membrane and to precipitate a core subdomain of Env in solution. The ability of HNP-1 to block HIV-1 uptake without interfering with constitutive endocytosis suggests a novel mechanism for broad activity against this and other viruses that enter cells through endocytic pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733823      PMCID: PMC3436536          DOI: 10.1074/jbc.M112.375949

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

1.  A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Authors:  Marielle Cavrois; Carlos De Noronha; Warner C Greene
Journal:  Nat Biotechnol       Date:  2002-09-30       Impact factor: 54.908

2.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

3.  Fluorescence correlation spectroscopy investigation of a GFP mutant-enhanced cyan fluorescent protein and its tubulin fusion in living cells with two-photon excitation.

Authors:  Zifu Wang; Jagesh V Shah; Zhongping Chen; Chung-Ho Sun; Michael W Berns
Journal:  J Biomed Opt       Date:  2004 Mar-Apr       Impact factor: 3.170

Review 4.  Defensins: antimicrobial peptides of innate immunity.

Authors:  Tomas Ganz
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

5.  Retrocyclin, an antiretroviral theta-defensin, is a lectin.

Authors:  Wei Wang; Alexander M Cole; Teresa Hong; Alan J Waring; Robert I Lehrer
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

6.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Productive folding of human neutrophil alpha-defensins in vitro without the pro-peptide.

Authors:  Zhibin Wu; Robert Powell; Wuyuan Lu
Journal:  J Am Chem Soc       Date:  2003-03-05       Impact factor: 15.419

8.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication.

Authors:  Miguel E Quiñones-Mateu; Michael M Lederman; Zhimin Feng; Bikram Chakraborty; Jan Weber; Hector R Rangel; Michael L Marotta; Muneer Mirza; Bin Jiang; Patti Kiser; Kathy Medvik; Scott F Sieg; Aaron Weinberg
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

10.  CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition.

Authors:  Theresa Li-Yun Chang; Fleur François; Arevik Mosoian; Mary E Klotman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  42 in total

1.  High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.

Authors:  Mariana Marin; Yuhong Du; Charline Giroud; Jeong Hwa Kim; Min Qui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2015-04-14       Impact factor: 1.738

2.  Peptide-Based Antiviral Drugs.

Authors:  N Arul Murugan; K Muruga Poopathi Raja; N T Saraswathi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Antimicrobial host defence peptides: functions and clinical potential.

Authors:  Neeloffer Mookherjee; Marilyn A Anderson; Henk P Haagsman; Donald J Davidson
Journal:  Nat Rev Drug Discov       Date:  2020-02-27       Impact factor: 84.694

4.  P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.

Authors:  Charline Giroud; Mariana Marin; Jason Hammonds; Paul Spearman; Gregory B Melikyan
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

5.  Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.

Authors:  Charline Giroud; Yuhong Du; Mariana Marin; Qui Min; Nathan T Jui; Haian Fu; Gregory B Melikyan
Journal:  Assay Drug Dev Technol       Date:  2017 Feb/Mar       Impact factor: 1.738

6.  3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.

Authors:  Minmin Li; Jiangman Duan; Jiayin Qiu; Fei Yu; Xiaoyan Che; Shibo Jiang; Lin Li
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-18       Impact factor: 2.205

7.  Click labeling of unnatural sugars metabolically incorporated into viral envelope glycoproteins enables visualization of single particle fusion.

Authors:  Yoon Hyeun Oum; Tanay M Desai; Mariana Marin; Gregory B Melikyan
Journal:  J Virol Methods       Date:  2016-03-29       Impact factor: 2.014

8.  Natural antimicrobial peptides as promising anti-HIV candidates.

Authors:  Guangshun Wang
Journal:  Curr Top Pept Protein Res       Date:  2012

Review 9.  Antiviral Activities of Human Host Defense Peptides.

Authors:  David C Brice; Gill Diamond
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

10.  Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.

Authors:  Miray Tonk; Daniel Růžek; Andreas Vilcinskas
Journal:  Viruses       Date:  2021-05-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.